Literature DB >> 8096560

Long-term malaria prophylaxis with weekly mefloquine.

H O Lobel1, M Miani, T Eng, K W Bernard, A W Hightower, C C Campbell.   

Abstract

The spread of chloroquine-resistant Plasmodium falciparum malaria has led to increased use of mefloquine prophylaxis by US Peace Corps volunteers in sub-Saharan Africa. We compared long-term mefloquine with other drug regimens for effectiveness and tolerance. The incidence of Plasmodium falciparum infections and of adverse reactions was compared in Peace Corps volunteers who took chloroquine weekly, mefloquine weekly, mefloquine every other week, or weekly chloroquine plus daily proguanil. Weekly mefloquine was 94% more effective than chloroquine (95% CI 86% to 97%), 86% more effective than chloroquine plus proguanil (95% CI 67% to 94%), and 82% more effective than prophylaxis with mefloquine when taken every other week (95% CI 68% to 90%). No serious adverse reactions were observed. Mild adverse events were equally frequent in mefloquine users and chloroquine users, and the frequency of these events declined with increasing duration of prophylaxis. Mefloquine is an effective and well-tolerated drug for prophylaxis of malaria by short-term and long-term travellers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096560     DOI: 10.1016/0140-6736(93)93058-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Review: Malaria chemoprophylaxis for travelers to Latin America.

Authors:  Laura C Steinhardt; Alan J Magill; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

3.  Mefloquine dangers - fact or fancy?

Authors:  J Keystone; K Kain
Journal:  Can J Infect Dis       Date:  1995-01

4.  Adverse events associated with mefloquine. Risk-benefit ratio must be taken into account.

Authors:  S Dollow
Journal:  BMJ       Date:  1996-12-14

5.  Approval of Tafenoquine for Malaria Chemoprophylaxis.

Authors:  Jonathan D Berman
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

6.  Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.

Authors:  Trevor N Johnson; Yumi Cleary; Neil Parrott; Bruno Reigner; James R Smith; Stephen Toovey
Journal:  Br J Clin Pharmacol       Date:  2018-11-05       Impact factor: 4.335

7.  Epilepsy triggered by mefloquine in an adult traveler to Uganda.

Authors:  Federico Gobbi; Andrea Rossanese; Dora Buonfrate; Andrea Angheben; Chiara Postiglione; Zeno Bisoffi
Journal:  World J Clin Cases       Date:  2014-01-16       Impact factor: 1.337

8.  Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.

Authors:  Geoffrey S Dow; Jun Liu; Gina Lin; Brian Hetzell; Sarah Thieling; William F McCarthy; Douglas Tang; Bryan Smith
Journal:  Malar J       Date:  2015-11-26       Impact factor: 2.979

Review 9.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  Illness in long-term travelers visiting GeoSentinel clinics.

Authors:  Lin H Chen; Mary E Wilson; Xiaohong Davis; Louis Loutan; Eli Schwartz; Jay Keystone; Devon Hale; Poh Lian Lim; Anne McCarthy; Effrossyni Gkrania-Klotsas; Patricia Schlagenhauf
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.